The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.

Compounds and compositions are disclosed in which a Drug Unit is linked to a targeting Ligand Unit through a self-stabilizing Linker Unit from which a drug compound or active drug moiety is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.

A method for exchange imaging of at least two targets in a sample includes (a) incubating a sample with at least two or more target-recognizing antibodies, each bound to a corresponding monovalent tight antibody binder-docketing moiety (MTAB-DM) reagent capable of binding monovalently to the target-recognizing antibodies, (b) applying at least two imager moieties corresponding to the MTAB-DM, either in series, in batches, or in parallel, and (d) imaging the at least two imager moieties either in series, in batches, or in parallel.

The present invention is directed to a platform for new bispecific targeting agents using liposomes or nanoparticles as linkers. The bispecific targeting agent can bind two different cell types, each via a separate targeting moiety. Said targeting agents can be used to induce specific biological effects in the cells such as cell proliferation or cell activation which can be used in some instances to destroy the other bound cells. Any cell that can be targeted can be subject to targeting. For example, the cell types that may be recruited by the bispecific targeting agent may be both human or one of the cells may be human and the other an infected cell or it can be an infectious agent. The platform is based on an empty nanoparticle or liposome conjugated to two or more targeting moieties, bound to the nanoparticle/liposome at defined ratios that may be other than 1:1. Such, compositions provide for specific binding to each cell type. This bispecific targeting agent can further be linked to growth factors or cytokines to further potentiate the effect of the bispecific targeting agent as a therapeutic or to exert a specific biologic effect on one or both cells being targeted.

The present disclosure provides a class of bifunctional compounds that includes an IGF-2 polypeptide that specifically binds to a cell surface cation independent mannose-6-phosphate receptor (CI-M6PR), and a target binding moiety. The bifunctional compounds can trigger the CI-M6PR cell surface receptor to internalize into the cell a complex of the target and the bifunctional compound. The target can be an extracellular target protein such as a soluble protein or a membrane bound target protein. The target binding moiety can be an antibody or antibody fragment. Also provided are methods of using the bifunctional compounds for sequestration and/or lysosomal degradation of a target, e.g., an extracellular target protein associated with a disease or disorder of interest.

An antibody-drug conjugate, comprising a bispecific antibody targeting HER2 or an antigen-binding fragment thereof. Also provided are a preparation method for and an application of the antibody-drug conjugate, and a pharmaceutical composition comprising the antibody-drug conjugate. The antibody-drug conjugate can effectively kill tumors.

The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.

The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.

A method for strengthening the immune response of a weakened immune system, wherein the method includes providing a doses of tissue resonance suppression therapy to a patient and injecting an autologous polyvalent biological vaccine to the patient, wherein the autologous polyvalent biological vaccine was produced from the patient venous blood, a system for performing tissue resonance suppression therapy, a system and a process for the production of the autologous polyvalent biological vaccine for treating cancer, and an autologous polyvalent biological vaccine for personalized and precision medicinal, for treatment of individual cancerous patients, wherein producing a new dose of autologous polyvalent biological vaccine is done from a patient venous blood that was taken after time interval from the time in which a previous venous blood was taken, wherein the vaccine is adapted for treating the individual cancerous patients at a specific stage of his disease, in accordance with embodiments of the present invention.

The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.